Articular Cartilage: Where it all started
The progenitor cells that form articular cartilage express a gene for a protein called NFATc1, which stops articular chondrocytes from developing too early in the joint.
- The First Affiliated Hospital of Xiamen University‐ICMRS Collaborating Center for Skeletal Stem Cell, State Key Laboratory of Cellular Stress Biology, Faculty of Medicine and Life Sciences, Xiamen University, China
- Fujian Provincial Key Laboratory of Organ and Tissue Regeneration, School of Medicine, Xiamen University, China
Articular cartilage is a smooth white tissue that covers the ends of bones where they join together. It is essential for maintaining the mobility of bone joints. However, despite this important role, the tissue is susceptible to degeneration caused by trauma, disease or ageing. This can lead to conditions such as osteoarthritis, which can cause chronic pain and, in some cases, disability (Cui et al., 2020).
Reversing damage to articular cartilage remains a great challenge in musculoskeletal medicine. One way to tackle this issue is to better understand how articular cartilage forms during embryonic development, as this knowledge could help researchers to develop new methods for rebuilding cartilage. Yet, the origins of the main cells in cartilage, known as articular chondrocytes, and the identity of the genes that regulate their production remain unclear. Now, in eLife, Xianpeng Ge (Capital Medical University in Beijing) and colleagues – including Fan Zhang and Yuanyuan Wang as joint first authors – report new insights into the formation of articular chondrocytes (Zhang et al., 2023).
Previous research has shown that the gene NFATc1 helps to regulate the development of bones by controlling cells that absorb and form bone (Winslow et al., 2006). To find out if NFATc1 could also be involved in cartilage development, Zhang et al. used genetically modified mouse embryos, in which cells expressing NFATc1 were tagged with a fluorescent marker that allowed the researchers to track these cells and their offspring over time. This revealed that NFATc1 is expressed in a group of progenitor cells throughout embryonic and even postnatal development, and that these cells are responsible for generating most of the articular chondrocytes (Figure 1).
Figure 1
The role of NFATc1 in articular cartilage formation.
Zhang et al. identified a unique progenitor cell population in the knee joint of embryonic mice (left) that expresses a gene called NFATc1, which has previously been linked to bone formation and bone resorption. These progenitor (stem) cells are responsible for generating articular chondrocytes – the main cell type in articular cartilage – during both embryonic and postnatal development (right). Suppressing the activity of NFATc1 in these stem progenitor cells induces the formation of chondrocytes, which are essential for forming articular cartilage.
Further experiments in cells and embryonic mice revealed that the expression of NFATc1 decreased as the articular chondrocytes matured. Zhang et al. found that when the gene was removed from the cartilage progenitors, the maturation of chondrocytes was faster and the formation of articular cartilage in embryos was still supported. Consistent with this, when NFATc1 was overactivated, the progenitor cells could no longer mature into chondrocytes. This indicates that this gene negatively regulates the development of articular chondrocytes.
So far, it has been challenging to track how articular cartilage develops as most genetic markers cannot distinguish between the different cell types in the relevant tissues (Rux et al., 2019; Chijimatsu and Saito, 2019). The only exception is the gene Prg4, a widely used marker of articular cartilage progenitors. But since cells only start to express this gene at a later stage during development, the marker fails to track their movement during the earlier stages (Kozhemyakina et al., 2015). In contrast, NFATc1 is expressed early during articular cartilage development, and may therefore offer a better alternative for studying the origin of articular cartilage.
It was previously thought that NFATc1, together with another gene involved in cartilage formation, NFATc2, restricts the overgrowth of cartilage (also known as osteochondroma) at the sites where the ligaments insert into the bone. However, adjusting how much of either of those genes was removed from the mice’s progenitor cells could in fact determine the number and size of osteochondromas (Ge et al., 2016). This knowledge may be helpful in understanding how NFATc1 may suppress the formation of cartilage in certain diseases.
It has been suggested that both NFATc1 and NFATc2 are key suppressors of osteoarthritis, which is crucial for articular cartilage formation in mice (Greenblatt et al., 2013). However, when Zhang et al. used a different approach to delete these two genes, they observed the opposite effect – removing NFATc1 and NFATc2 enhanced chondrogenesis under pathological conditions. This suggests that researchers should carefully consider the genetic ablating tools they use when studying the role of progenitor cells in articular cartilage.
Moreover, it has been shown that adult skeletal stem cells expressing NFATc1 behave as bone-cell progenitors and contribute to the early stages of repair following a bone fracture (Yu et al., 2022). This highlights the complex pool of progenitor cells that express NFATc1, and how the fate of these progenitors changes during different periods of development as well as adulthood. More importantly, to date, it remains unclear whether these NFATc1-expressing progenitor cells fulfill stemness criteria in the skeleton, such as stem-cell transplantation (Debnath et al., 2018), or if these cells are able to generate functional articular cartilage.
Despite a lack of evidence confirming the stemness of NFATc1-expressing progenitor cells, the work of Zhang et al. offers researchers an additional genetic tool to detect and track the origins of articular chondrocytes. Moreover, their findings provide valuable insights into the mechanism of articular cartilage formation. If studies in human cells achieve similar results, this may help scientists to identify potential treatments of cartilage diseases, such as osteoarthritis.
References
-
Mechanisms of synovial joint and articular cartilage developmentCellular and Molecular Life Sciences 76:3939–3952.https://doi.org/10.1007/s00018-019-03191-5
-
Identification of a Prg4-expressing articular cartilage progenitor cell population in miceArthritis & Rheumatology 67:1261–1273.https://doi.org/10.1002/art.39030
-
Joints in the appendicular skeleton: developmental mechanisms and evolutionary influencesCurrent Topics in Developmental Biology 133:119–151.https://doi.org/10.1016/bs.ctdb.2018.11.002
-
Calcineurin/NFAT signaling in osteoblasts regulates bone massDevelopmental Cell 10:771–782.https://doi.org/10.1016/j.devcel.2006.04.006
Article and author information
Author details
Publication history
Copyright
© 2023, Zhang et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 602
- views
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Articular Cartilage: Where it all started
eLife 12:e87355.
https://doi.org/10.7554/eLife.87355
Further reading
-
- Medicine
Background:
Post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis (PEP) is a severe and deadly adverse event following ERCP. The ideal method for predicting PEP risk before ERCP has yet to be identified. We aimed to establish a simple PEP risk score model (SuPER model: Support for PEP Reduction) that can be applied before ERCP.
Methods:
This multicenter study enrolled 2074 patients who underwent ERCP. Among them, 1037 patients each were randomly assigned to the development and validation cohorts. In the development cohort, the risk score model for predicting PEP was established via logistic regression analysis. In the validation cohort, the performance of the model was assessed.
Results:
In the development cohort, five PEP risk factors that could be identified before ERCP were extracted and assigned weights according to their respective regression coefficients: –2 points for pancreatic calcification, 1 point for female sex, and 2 points for intraductal papillary mucinous neoplasm, a native papilla of Vater, or the pancreatic duct procedures (treated as ‘planned pancreatic duct procedures’ for calculating the score before ERCP). The PEP occurrence rate was 0% among low-risk patients (≤0 points), 5.5% among moderate-risk patients (1–3 points), and 20.2% among high-risk patients (4–7 points). In the validation cohort, the C statistic of the risk score model was 0.71 (95% CI 0.64–0.78), which was considered acceptable. The PEP risk classification (low, moderate, and high) was a significant predictive factor for PEP that was independent of intraprocedural PEP risk factors (precut sphincterotomy and inadvertent pancreatic duct cannulation) (OR 4.2, 95% CI 2.8–6.3; p<0.01).
Conclusions:
The PEP risk score allows an estimation of the risk of PEP prior to ERCP, regardless of whether the patient has undergone pancreatic duct procedures. This simple risk model, consisting of only five items, may aid in predicting and explaining the risk of PEP before ERCP and in preventing PEP by allowing selection of the appropriate expert endoscopist and useful PEP prophylaxes.
Funding:
No external funding was received for this work.
-
- Medicine
Estrogen significantly impacts women’s health, and postmenopausal hypertension is a common issue characterized by blood pressure fluctuations. Current control strategies for this condition are limited in efficacy, necessitating further research into the underlying mechanisms. Although metabolomics has been applied to study various diseases, its use in understanding postmenopausal hypertension is scarce. Therefore, an ovariectomized rat model was used to simulate postmenopausal conditions. Estrogen levels, blood pressure, and aortic tissue metabolomics were analyzed. Animal models were divided into Sham, OVX, and OVX +E groups. Serum estrogen levels, blood pressure measurements, and aortic tissue metabolomics analyses were performed using radioimmunoassay, UHPLC-Q-TOF, and bioinformatics techniques. Based on the above research content, we successfully established a correlation between low estrogen levels and postmenopausal hypertension in rats. Notable differences in blood pressure parameters and aortic tissue metabolites were observed across the experimental groups. Specifically, metabolites that were differentially expressed, particularly L-alpha-aminobutyric acid (L-AABA), showed potential as a biomarker for postmenopausal hypertension, potentially exerting a protective function through macrophage activation and vascular remodeling. Enrichment analysis revealed alterations in sugar metabolism pathways, such as the Warburg effect and glycolysis, indicating their involvement in postmenopausal hypertension. Overall, this current research provides insights into the metabolic changes associated with postmenopausal hypertension, highlighting the role of L-AABA and sugar metabolism reprogramming in aortic tissue. The findings suggest a potential link between low estrogen levels, macrophage function, and vascular remodeling in the pathogenesis of postmenopausal hypertension. Further investigations are needed to validate these findings and explore their clinical implications for postmenopausal women.
